Skip to main content

Table 2 Prognostic factors for disease-free survival (DFS): univariate analysis

From: Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

 

N

5-Year DFS (%) (95 % CI)

HR (95 % CI)

p-valuea

Age

  < 35

30

82.6 [68.2–100]

1

 

  ≥ 35

726

90.9 [88.5–93.4]

0.5 [0.2–1.3]

0.136

SBR Grade

 1–2

462

93.2 [90.5–95.9]

1

 

 3

285

86 [81.4–91]

1.8 [1.1–2.9]

0.0138

Pathological tumor size

 pT1

391

91.2 [87.9–94.5]

1

 

 pT2

320

90 [86.2–94]

1.1 [0.7–1.8]

 

 pT3-T4

36

88.2 [78–99.8]

1.1 [0.4–3]

0.9514

PVI

 No

558

92.3 [89.7–95]

1

 

 Yes

178

85 [79–91.4]

2.3 [1.4–3.7]

0.0007

Hormone receptors

 Negative

208

86.8 [81.6–92.4]

1

 

 Positive

526

92.5 [89.9–95.2]

0.7 [0.4–1.1]

0.1059

HER2

 Negative

507

91 [88–94.1]

1

 

 Positive

96

95.7 [91–100]

0.6 [0.2–1.6]

0.376

IHC subtypes

 Luminal A

289

95.1 [92.1–98.2]

1

 

 Luminal B/HER2-negative

82

80.1 [69.8–92]

4.3 [2–9.1]

 

 Luminal B/HER2-positive

58

100 [100–100]

0.7 [0.2–3.3]

 

 HER2

37

89 [77.6–100]

1.8 [0.5–6.2]

 

 Triple-negative

127

87.6 [80.7–95]

2.6 [1.2–5.5]

0.0006

  1. HR hazard ratio, PVI peritumor vascular invasion
  2. aunadjusted log-rank test